Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 14, 2026
The registrant is a foreign private issuer based in Ramat Gan, Israel, filing to incorporate a press release by reference into its Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate development event and does not contain financial statements or quantitative financial data.
Material Changes
Intellectual Property Development: On July 14, 2026, the company secured an Australian patent allowance supporting the development and marketing of its lead candidate, Namodenoson, specifically for liver and pancreatic cancer indications.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release highlighting the strategic milestone of the Australian patent allowance, which supports the commercialization pathway for Namodenoson in the specified oncology indications.
Risks and Contingencies: The filing text does not explicitly detail new risks, contingencies, or unusual items beyond the standard incorporation of the press release.
Investor Verification Checklist
- Verify the scope and validity of the Australian patent allowance for Namodenoson in liver and pancreatic cancer.
- Review the full text of the press release (Exhibit 99.1) for specific details on the patent claims and regulatory implications.
- Confirm the status of Namodenoson clinical trials in other jurisdictions to assess the global commercial strategy.
- Check subsequent filings for any financial impact or updated guidance related to this IP milestone.